Related Experiment Video
Updated: Jan 29, 2026
Experience is Instrumental in Tuning a Link Between Language and Cognition: Evidence from 6- to 7- Month-Old Infants' Object Categorization
Published on: April 19, 2017
Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
Mikio Kamimura1, Yukio Nakamura2, Shota Ikegami2
1Center for Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic, Nagano, Japan.
Abstract:
As a bisphosphonate, minodronate (MIN) is one of the strongest inhibitors of bone resorption. However, there have been no reports directly comparing the antiresorptive effects of monthly MIN with those of monthly risedronate (RIS). We enrolled 30 cases of osteoporosis (OP; 16 in the MIN group [mean age: 68.2 years] and 14 in the RIS group [mean age: 68.1 years]) to investigate the early effects of treatment by monthly MIN or RIS over a 4-month period using bone turnover marker values. Only female patients were enrolled to avoid gender bias. Urinary cross-linked N-telopeptide of type I collagen (NTX) before treatment and at 1, 2, and 4 months of therapy, as well as serum bone alkaline phosphatase and alkaline phosphatase before treatment and at 4 months afterwards, were evaluated. All bone turnover marker values were significantly decreased at 4 months in both groups. The changes in urinary NTX at the study end point for RIS and MIN were -30.1% and -63.1%, respectively. From 2 months of treatment, the antiresorptive effects on urinary NTX by MIN were significantly higher than those by RIS, indicating that MIN more immediately and strongly inhibited bone absorption. Thus, monthly MIN seems to suppress bone resorption faster and more strongly than RIS in OP treatment.
Insights
Minodronate (MIN) and risedronate (RIS) both treat osteoporosis by inhibiting bone resorption. Monthly MIN demonstrated significantly stronger and faster reductions in bone turnover markers compared to monthly RIS over four months.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Bisphosphonates are potent inhibitors of bone resorption.
- Minodronate (MIN) and risedronate (RIS) are established bisphosphonates for osteoporosis.
- Direct comparative data on the early antiresorptive effects of monthly MIN versus RIS is limited.
Purpose of the Study:
- To compare the early antiresorptive effects of monthly minodronate (MIN) versus monthly risedronate (RIS) in patients with osteoporosis.
- To evaluate the impact of these treatments on bone turnover markers over a four-month period.
Main Methods:
- A 4-month study involving 30 female patients with osteoporosis (16 in MIN group, 14 in RIS group).
- Measurement of urinary cross-linked N-telopeptide of type I collagen (NTX) at baseline and at 1, 2, and 4 months.
- Assessment of serum bone alkaline phosphatase and alkaline phosphatase at baseline and 4 months.
Main Results:
- Both monthly MIN and RIS significantly decreased bone turnover markers by 4 months.
- Urinary NTX decreased by -30.1% for RIS and -63.1% for MIN at 4 months.
- Minodronate showed significantly greater inhibition of urinary NTX from 2 months onwards compared to risedronate.
Conclusions:
- Monthly minodronate appears to suppress bone resorption more rapidly and effectively than monthly risedronate in osteoporosis treatment.
- Minodronate demonstrates a stronger early antiresorptive effect compared to risedronate.
Related Concept Videos
00:46Feedback Inhibition
01:30Enzyme Inhibition
02:34Inhibition of Cdk Activity
01:55Bone Structure
01:40Bone Remodeling
01:27Compact Bone
Compact bone, also called cortical bone, is the denser, stronger of the two types of bone tissue. It is found under the periosteum and in the diaphyses of long bones, where it provides support and protection. The microscopic structural unit of compact bone is called an osteon, or haversian system. Each osteon is composed of concentric rings of calcified...